Pfizer Inc., of New York, said that the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending Xeljanz (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis (RA).